Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01852162 · ClinicalTrials.gov registry record · NA
Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy
A NA study, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 35
- Enrollment target
NCT01852162 is a NA study that has completed, run by University of Florida. The registered enrollment target is 35 participants.
The verdict
NCT01852162, a NA study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
Study Summary
Dual antiplatelet therapy consisting of aspirin and clopidogrel is the cornerstone of treatment for prevention of atherothrombotic events in patients with coronary artery disease (CAD) undergoing percutaneous coronary interventions (PCI). Many patients on dual antiplatelet therapy in this setting may be affected by other thromboembolic conditions, in particular atrial fibrillation, therefore having an indication to also receive oral anticoagulation for stroke prevention. Thus, a considerable percentage of patients are under "triple therapy" which consists of aspirin plus clopidogrel plus an oral anticoagulant. The ever raising population with CAD warranting triple therapy and the growing number of patients being treated with dabigatran underscores the importance of understanding the pharmacodynamic effects of this treatment regimen.
Interventions
- DRUG Placebo
- DRUG Dabigatran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01852162
The ClinicalTrials.gov registry entry for NCT01852162 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01852162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01852162 about?
NCT01852162 is a clinical study titled "Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy". Dual antiplatelet therapy consisting of aspirin and clopidogrel is the cornerstone of treatment for prevention of atherothrombotic events in patients with coronary artery disease (CAD) undergoing percutaneous coronary interventions (PCI). Many patients on dual antiplatelet therapy in this setting ma...
What is the current status of trial NCT01852162?
This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2012-02. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01852162?
The interventions under investigation include: Placebo (DRUG), Dabigatran (DRUG).
Who is sponsoring clinical trial NCT01852162?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.